The association between PLCD1 and IMPA2 in Group 1 in each age interval also is of interest because IMPA2, which dephosphorylates myo-inositol monophosphate within the “PI cycle”, has been proposed as the preferred target of lithium in the treatment bipolar disorder [59–61]. This evidence concerns the gene IMPA2 and bipolar disorder.